An interventional study of Bupivacaine-Lidocaine Combination and Bupivacaine in Lower Extremity, Nerve Block and Pain, Postoperative, sponsored by Ataturk University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Ataturk University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Pain, Postoperative by Ataturk University — 10 open to participants now, 11 under way, none of them phase 3. Pain, Postoperative · Ataturk University.
Among the 34 studies in Pain, Postoperative by Ataturk University, this one is the 21st largest by planned enrollment, is one of 7 that started in 2025, is one of 33 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 29th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →10 of the 34 studies in Pain, Postoperative by Ataturk University are open now, in 1 country. Recruiting first, the newest first:
Ataturk University · Sites in Turkey
Ages 18–65 · Women only
Ataturk University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Ataturk University · Sites in Turkey
Ataturk University
Ages 18–65
Ataturk University · Sites in Turkey
Ages 18+
By country, each count listing its studies:
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 65 across the 34 interventional studies. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ataturk University is the lead sponsor of 463 studies on the registry; 123 are open to participants now.
4 of the studies in Pain, Postoperative by Ataturk University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07550348Ataturk UniversityBupivacaine-Lidocaine vs Bupivacaine for Ultrasound-Guided Popliteal Sciatic Nerve Block | 2026-12-01 |
| NCT07930533Ataturk UniversityBioceramic Versus Epoxy Resin-Based Root Canal Sealer and Postoperative Pain After Warm Vertical Compaction | 2027-01-10 |
| NCT07858058Ataturk UniversityThe Effect of White and Pink Noise in Patients Undergoing Total Hip and Knee Arthroplasty | 2027-03-15 |
| NCT07858045Ataturk UniversityVideo-Assisted Patient Education and Eye Fixation Training in Pterygium Surgery | 2027-10-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Pain, Postoperative by Ataturk University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, randomized, double-blind clinical trial aims to compare the efficacy of two local anesthetic regimens for ultrasound-guided popliteal sciatic nerve block in adult patients undergoing elective distal lower extremity surgery.
Eligible participants (ages 18-65, ASA physical status I-III, BMI 18-35 kg/m²) will be randomized into two equal groups of 30. Patients in Group BL will receive a combination of 10 mL 2% lidocaine and 10 mL 0.5% bupivacaine, while patients in Group B will receive 20 mL 0.5% bupivacaine alone, administered via ultrasound-guided popliteal sciatic nerve block prior to surgery.
The primary outcome is the onset time of sensory and motor blockade. Secondary outcomes include block success rate, duration of sensory and motor block, postoperative opioid consumption, pain scores assessed by the Numeric Rating Scale (NRS) at 2, 4, 8, 12, and 24 hours postoperatively, Quality of Recovery-15 (QoR-15) score, and incidence of rebound pain.
The study is conducted at Ataturk University Research Hospital, Department of Anesthesiology and Reanimation, Erzurum, Turkey.
Background and Rationale
Peripheral nerve blocks have become an increasingly preferred technique for both anesthesia and analgesia in distal lower extremity surgery, offering advantages such as reduced opioid consumption, stable intraoperative hemodynamics, lower rates of postoperative nausea and vomiting, and enhanced early mobilization. The popliteal approach to the sciatic nerve provides effective surgical anesthesia for foot, ankle, and distal leg procedures, with high patient satisfaction and a low complication profile. Ultrasound guidance further improves block success rates by enabling direct visualization of perineural anatomical structures.
The choice of local anesthetic plays a critical role in determining block onset time, duration of sensory and motor blockade, and overall analgesic duration. Lidocaine offers rapid onset and short-to-intermediate duration, while bupivacaine provides prolonged sensory and motor blockade, thereby reducing postoperative opioid requirements. The combination of these two agents theoretically enables simultaneous achievement of rapid onset and prolonged analgesia; however, the net effect of this combination on block characteristics remains inconclusive in the current literature.
Study Design
This is a prospective, randomized, double-blind, single-center, two-arm parallel-group clinical trial conducted at Ataturk University Research Hospital, Department of Anesthesiology and Reanimation, Erzurum, Turkey.
Participants
A total of 60 adult patients scheduled for elective distal lower extremity surgery will be enrolled. Inclusion criteria: age 18-65 years, ASA physical status I-III, body mass index (BMI) 18-35 kg/m², and written informed consent. Exclusion criteria include inability to provide informed consent, coagulopathy, sepsis, hepatic or renal insufficiency, known allergy to local anesthetics, prior surgery or significant scar tissue in the popliteal fossa, pregnancy, and chronic opioid use at home.
Randomization and Blinding
Eligible patients will be randomized in a 1:1 ratio using a computer-generated random number list into two groups of 30. Study solutions will be prepared by a dedicated investigator not involved in block performance or outcome assessment. Patients and the outcome assessor will be blinded to group allocation (double-blind). The anesthesiologist performing the block will be aware of the group allocation. Block procedures will be performed by an anesthesiologist with a minimum of two years of experience in ultrasound-guided regional anesthesia who is not involved in patient care.
Intervention
All patients will receive an ultrasound-guided popliteal sciatic nerve block using a total volume of 20 mL local anesthetic solution. Patients will be positioned prone or in lateral decubitus with the operative limb uppermost and the knee in slight flexion. Under aseptic conditions, a high-frequency linear ultrasound probe will be placed transversely over the popliteal fossa to visualize the popliteal artery and the tibial nerve. The probe will be advanced proximally to identify the tibial and common peroneal nerve bifurcation. A 100 mm echogenic block needle will be advanced in-plane from lateral to medial. After confirming circumferential perineural spread of 1-2 mL test injection under ultrasound guidance, the study solution will be incrementally injected with repeated aspiration checks.
Group BL (n=30): 10 mL 2% lidocaine + 10 mL 0.5% bupivacaine (administered sequentially in separate syringes)
Group B (n=30): 20 mL 0.5% bupivacaine (administered in two 10 mL syringes) In cases involving the medial malleolus or medial leg surface, an additional adductor canal block will be performed using 10 mL of the respective study solution.
Intraoperative Management Conscious sedation will be maintained intraoperatively with intravenous dexmedetomidine (loading dose: 0.5-1 µg/kg over 10 minutes; maintenance: 0.2-0.7 µg/kg/hour). Continuous monitoring of heart rate, non-invasive blood pressure, oxygen saturation, and electrocardiography will be performed throughout the procedure.
Postoperative Analgesia Protocol All patients will receive intravenous paracetamol 1000 mg 30 minutes before the end of surgery, repeated every 8 hours postoperatively. Intravenous dexketoprofen 50 mg will be administered intraoperatively and repeated every 12 hours. Rescue analgesia with intravenous tramadol 100 mg will be administered for NRS ≥ 4, with a maximum of 3 doses per day and a minimum interval of 4-6 hours between doses.
Outcome Measures Primary Outcome: The primary outcome is the duration of sensory block. It is defined as the time to return of sensation in the postoperative period, i.e., the time at which the patient first reports regaining sensation in the toes. Sensory function will be assessed at 1, 2, 4, 8, 12, and 24 hours postoperatively. The time of sensory recovery will be confirmed by in-person visit or telephone interview at 24, 48, and 72 hours after block performance.
Secondary Outcomes:
Block onset time: Time elapsed from completion of local anesthetic injection to first achievement of block success criteria.
Block success rate: Proportion of patients achieving a total sensorimotor score ≥12/14 with a sensory score ≥7/8 within 60 minutes of injection.
Adequacy of surgical anesthesia: Completion of surgery without the need for supplemental general anesthesia or local infiltration at the surgical site.
Duration of motor block: Time to return of motor function in the postoperative period, i.e., the time at which the patient is first able to move the toes. Motor function will be assessed at 1, 2, 4, 8, 12, and 24 hours postoperatively.
Duration of analgesia: Time to first reported pain after block performance. Postoperative pain scores: Pain intensity assessed using the Numeric Rating Scale (NRS 0-10) at 1, 2, 4, 8, 12, and 24 hours postoperatively. The highest NRS score will additionally be recorded at 24, 48, and 72 hours.
Quality of recovery: QoR-15 score (0-150; higher scores indicate better recovery) assessed preoperatively (baseline) and at 24 hours postoperatively.
Incidence of rebound pain: Defined as NRS ≥7 within 24 hours after resolution of the sensory block.
Neurological complications: Presence of paresthesia, numbness, or motor deficit in the blocked extremity, assessed by telephone interview or outpatient clinic visit on postoperative day 7.
Block Assessment
Sensory block will be assessed using the pinprick test across four nerve territories: tibial (plantar aspect of the foot), deep peroneal (first web space), superficial peroneal (dorsum of the foot), and sural (lateral border of the fifth metatarsal). Each territory will be scored from 0 to 2 (0 = normal sensation; 1 = analgesia, i.e., the patient perceives touch but not pinprick; 2 = anesthesia, i.e., the patient perceives neither touch nor pinprick), giving a maximum score of 8.
Motor block will be evaluated across three nerve territories: tibial (ankle plantar flexion), deep peroneal (ankle dorsiflexion), and superficial peroneal (foot eversion). Each territory will be scored from 0 to 2 (0 = normal; 1 = paresis; 2 = paralysis), giving a maximum score of 6.
The total maximum sensorimotor score is 14. Successful block is defined as a total score ≥12/14 with a sensory score ≥7/8. Blocks not achieving success criteria within 60 minutes will be considered failed. Patients with a successful block will then be transferred to the operating room.
Statistical Analysis Continuous variables will be assessed for normality using the Shapiro-Wilk test. Normally distributed variables will be compared using the independent samples t-test; non-normally distributed variables using the Mann-Whitney U test. Categorical variables will be analyzed using Fisher's exact chi-square test. A p-value \<0.05 will be considered statistically significant. Statistical analyses will be performed using SPSS (IBM, Armonk, NY) or R (v4.2, Vienna, Austria).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ultrasound-guided popliteal sciatic nerve block with 10 mL 2% lidocaine + 10 mL 0.5% bupivacaine administered sequentially in separate syringes (total volume: 20 mL).
Drug: Bupivacaine-Lidocaine Combination
Ultrasound-guided popliteal sciatic nerve block with 20 mL 0.5% bupivacaine administered in two 10 mL syringes (total volume: 20 mL).
Drug: Bupivacaine
Ultrasound-guided popliteal sciatic nerve block with 10 mL 2% lidocaine and 10 mL 0.5% bupivacaine administered sequentially in separate syringes (total volume: 20 mL).
Also known as: Lidocaine 2% + Bupivacaine 0.5%
Ultrasound-guided popliteal sciatic nerve block with 20 mL 0.5% bupivacaine administered in two separate 10 mL syringes (total volume: 20 mL).
Also known as: Bupivacaine 0.5%
Duration of Sensory Block
Time to return of sensation in the postoperative period, defined as the time at which the patient first reports regaining sensation in the toes. Sensory function will be assessed at 1, 2, 4, 8, 12, and 24 hours postoperatively by an outcome assessor blinded to group allocation, and the time of sensory recovery will be confirmed by in-person visit or telephone interview at 24, 48, and 72 hours after block performance.
Time frame: Postoperative 1, 2, 4, 8, 12, and 24 hours; confirmed at 24, 48, and 72 hours after block performance
Block Success Rate
Proportion of patients achieving a total sensorimotor score ≥12/14 with a sensory score ≥7/8 within 60 minutes of injection.
Time frame: Within 60 minutes after injection
Duration of Motor Block
Time to return of motor function in the postoperative period, defined as the time at which the patient is first able to move the toes. Motor function will be assessed at 1, 2, 4, 8, 12, and 24 hours postoperatively and confirmed by in-person visit or telephone interview at 24, 48, and 72 hours after block performance.
Time frame: Up to 72 hours after block application
Postoperative Pain Score
Pain intensity assessed using the Numeric Rating Scale (NRS, 0-10; 0 = no pain, 10 = worst imaginable pain) at 1, 2, 4, 8, 12, and 24 hours postoperatively. The highest NRS score will additionally be recorded at 24, 48, and 72 hours after block performance.
Time frame: At 1, 2, 4, 8, 12, 24, 48, and 72 hours postoperatively
Quality of Recovery-15 (QoR-15) Score
Patient-reported quality of recovery assessed using the validated QoR-15 questionnaire, comprising 15 items across five dimensions (physical comfort, physical independence, psychological support, emotional state, and pain). Total score ranges from 0 to 150, with higher scores indicating better recovery. The questionnaire will be administered preoperatively (baseline) and at 24 hours postoperatively.
Time frame: Preoperatively (baseline) and at 24 hours postoperatively
Incidence of Rebound Pain
Proportion of patients experiencing rebound pain, defined as NRS ≥7 within 24 hours after resolution of the sensory block.
Time frame: Within 24 hours after sensory block resolution, up to 72 hours postoperatively
Neurological Assessment at Postoperative Day 7
Presence of any neurological sequelae including paresthesia, numbness, or motor deficit in the blocked extremity, assessed by telephone interview or clinic visit at postoperative day 7.
Time frame: Postoperative day 7
Sensory and Motor Block Onset Time
Time elapsed from completion of local anesthetic injection to first achievement of block success criteria, defined as a total sensorimotor score ≥12/14 and sensory score ≥7/8. Blocks not meeting success criteria within 60 minutes will be considered failed.
Time frame: From completion of injection up to 60 minutes
Adequacy of Surgical Anesthesia
Proportion of patients in whom surgery is completed without the need for supplemental general anesthesia or local infiltration at the surgical site.
Time frame: Intraoperative
Duration of Analgesia
Time to first reported pain after block performance, recorded by patient interview and confirmed by in-person visit or telephone interview at 24, 48, and 72 hours after block performance.
Time frame: Up to 72 hours after block performance
Postoperative Pain Assessed by Visual Analogue Scale (VAS)
Postoperative pain intensity assessed using a 10-cm Visual Analogue Scale (VAS; 0 = no pain, 10 = worst imaginable pain) at 1, 2, 4, 8, 12, and 24 hours postoperatively by an outcome assessor blinded to group allocation.
Time frame: At 1, 2, 4, 8, 12, and 24 hours postoperatively
Time to First Postoperative Mobilization
Time elapsed from the end of surgery to the patient's first mobilization, defined as getting out of bed and ambulating with or without assistance (including the use of crutches or a walker, according to the weight-bearing status prescribed by the surgical team). The time of first mobilization will be recorded by an outcome assessor blinded to group allocation and confirmed by patient interview.
Time frame: From the end of surgery up to 72 hours postoperatively
Time to First Rescue Opioid Requirement
Time elapsed from the end of surgery to the first administration of intravenous rescue tramadol, given when the postoperative pain score reaches NRS ≥4. Patients who do not require rescue opioid analgesia during the follow-up period will be recorded as censored at 72 hours.
Time frame: From the end of surgery up to 72 hours postoperatively
Plan to share: No
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 12 months is close to that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.